|

LAG3 Expression in Triple Negative Breast Cancer

RECRUITINGN/ASponsored by Samsung Medical Center
Actively Recruiting
PhaseN/A
SponsorSamsung Medical Center
Started2022-11-18
Est. completion2025-07-01
Eligibility
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06259162

Summary

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Eligibility

Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Planned neoadjuvant chemotherapy
* Triple negative breast cancer

Exclusion Criteria:

* HER2-positive breast cancer
* Hormone receptor positive breast cancer

Conditions4

Breast CancerCancerImmune Checkpoint InhibitorTriple Negative Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.